Joshua Ziel

A scientist by training, Dr Ziel has spent his career working within and around Pharma and Biotech on some of the most consequential products in hematology-oncology, rare disease, and respiratory. He brings a unique blend of strategic insight and operational expertise gleaned from working across the product development lifecycle, from early clinical development to commercialization. Dr. Ziel joined Aerami in 2022 based on his belief in the potential of Aerami’s lead asset AER-901 to treat multiple forms of pulmonary hypertension and leads R&D efforts for the company’s pipeline of inhaled therapies for pulmonary hypertension.